Non-Melanoma Skin Cancer Occurring in Patients Treat After First Treatment

Journal of Investigative Dermatology 91, 120-124

DOI: 10.1111/1523-1747.ep12464137

Citation Report

#	Article	IF	CITATIONS
1	Commentary on Oral Methoxsalen Photochemotherapy for the Treatment of Psoriasis: A Cooperative Clinical Trial: From Napkin Notes to Notabilia. Journal of Investigative Dermatology, 1989, 92, S154-S156.	0.3	1
2	The State of Research in Cutaneous Biology: A Perspective in the 50th Anniversary Year of the Society for Investigative Dermatology and The Journal of Investigative Dermatology. Journal of Investigative Dermatology, 1989, 92, S179-S197.	0.3	3
3	Cancer Risk Associated With Therapeutic Irradiation of Skin. Archives of Dermatology, 1989, 125, 979.	1.7	11
4	The Epidemic of Squamous Cell Carcinoma. JAMA - Journal of the American Medical Association, 1989, 262, 2138.	3.8	46
5	Risk Assessment of PUVA and Cyclosporine. Archives of Dermatology, 1989, 125, 545.	1.7	10
6	Commentary on Oral Methoxsalen Photochemotherapy for the Treatment of Psoriasis: A Cooperative Clinical Trial: From Napkin Notes to Notabilia Journal of Investigative Dermatology, 1989, 92, 153S-156S.	0.3	2
8	RECENT ADVANCES IN PSORALEN PHOTOTOXICITY MECHANISM. Photochemistry and Photobiology, 1989, 50, 859-882.	1.3	221
9	Carcinogenesis: A Fifty-Year Historical Perspective. Journal of Investigative Dermatology, 1989, 92, S121-S131.	0.3	13
10	Six Citation Classics from The Journal of Investigative Dermatology. Journal of Investigative Dermatology, 1989, 92, S149-S150.	0.3	1
11	Genital Tumors among Men with Psoriasis Exposed to PUVA. New England Journal of Medicine, 1990, 323, 684-685.	13.9	3
12	Side-effects of psoralen photochemotherapy (PUVA). British Journal of Dermatology, 1990, 122, 117-125.	1.4	70
13	Photocarcinogenicity of psoralens used in PUVA treatment: Present status in mouse and man. Journal of Photochemistry and Photobiology B: Biology, 1990, 6, 237-247.	1.7	48
14	Association of nonmelanoma skin cancer and actinic keratosis with cumulative solar ultraviolet exposure in Maryland watermen. Cancer, 1990, 65, 2811-2817.	2.0	270
15	Phototherapy and Photochemotherapy. New England Journal of Medicine, 1990, 322, 1149-1151.	13.9	26
16	Book Reviews : Mechanisms Involved in Photobiologic Reactions of the Skin. Journal of the Royal Society of Health, 1990, 110, 228-228.	0.2	0
17	Overview of Radiation-induced Skin Cancer in Humans. International Journal of Radiation Biology, 1990, 57, 809-827.	1.0	81
18	Recent advances in phototherapy and photochemotherapy of skin disease. Journal of Dermatological Science, 1990, 1, 141-147.	1.0	5
19	Dermatologic therapy: December 1987 to December 1988. Journal of the American Academy of Dermatology, 1990, 22, 231-238.	0.6	O

#	Article	IF	CITATIONS
21	Genital Tumors among Men with Psoriasis Exposed to Psoralens and Ultraviolet A Radiation (PUVA) and Ultraviolet B Radiation. New England Journal of Medicine, 1990, 322, 1093-1097.	13.9	315
22	Therapeutic potential of plant photosensitizers. , 1991, 49, 181-222.		94
23	"High single-dose' European PUVA regimen also causes an excess of non-melanoma skin cancer. British Journal of Dermatology, 1991, 124, 49-55.	1.4	114
24	A study of elastic tissue and actinic radiation in "aging,―temporal arteritis, polymyalgia rheumatica, and atherosclerosis. Journal of the American Academy of Dermatology, 1991, 24, 765-776.	0.6	43
25	PUVA and cancer: a large-scale epidemiological study. Lancet, The, 1991, 338, 91-93.	6.3	242
26	Genital carcinomas in psoriasis patients treated with photochemotherapy. Lancet, The, 1991, 337, 439.	6.3	5
27	PUVA and cancer. Lancet, The, 1991, 338, 703-704.	6.3	3
28	Biology of basal cell carcinoma (Part II). Journal of the American Academy of Dermatology, 1991, 24, 161-175.	0.6	123
30	Relative efficacy of 335 and 365 nm radiation in photochemotherapy of psoriasis. British Journal of Dermatology, 1991, 124, 372-374.	1.4	19
31	Effects of In Vitro UVA Irradiation and PUVA Treatment on Membrane Fatty Acids and Activities of Antioxidant Enzymes in Human Keratinocytes. Journal of Investigative Dermatology, 1991, 96, 255-259.	0.3	92
32	Local Suppression of Contact Hypersensitivity in Mice by a New Bifunctional Psoralen, 4,4',5'-trimethylazapsoralen, and UVA Radiation. Journal of Investigative Dermatology, 1991, 97, 50-54.	0.3	14
33	Nonmelanoma Cancers of the Skin. New England Journal of Medicine, 1992, 327, 1649-1662.	13.9	534
34	Comparison of the Carcinogenic Potential of Trioxsalen Bath PUVA and Oral Methoxsalen PUVA. Archives of Dermatology, 1992, 128, 1341.	1.7	49
35	Recent Advances in Dermatology. New England Journal of Medicine, 1992, 326, 167-178.	13.9	22
36	PUVA and skin cancer. Journal of the American Academy of Dermatology, 1992, 26, 173-177.	0.6	107
37	Biology of cutaneous squamous cell carcinoma. Journal of the American Academy of Dermatology, 1992, 26, 1-26.	0.6	282
38	Human models of melanoma. Clinics in Dermatology, 1992, 10, 83-89.	0.8	9
39	The effects of non-interval PUVA treatment on Langerhans cells and contact hypersensitivity. Journal of Dermatological Science, 1992, 3, 91-96.	1.0	5

#	ARTICLE	IF	Citations
40	Malignant tumors in patients with psoriasis. Journal of the American Academy of Dermatology, 1992, 27, 716-722.	0.6	77
41	PUVA augments cyclosporine A-mediated rat cardiac allograft survival. Journal of Surgical Research, 1992, 52, 565-570.	0.8	1
42	Cutaneous and Ocular Ramifications of Ultraviolet Radiation. Dermatologic Clinics, 1992, 10, 483-504.	1.0	4
43	Fate of [14C]xanthotoxin (8-methoxypsoralen) in laying hens and a lactating goat. Journal of Chemical Ecology, 1992, 18, 253-270.	0.9	8
44	A reappraisal of the use of 5-methoxypsoralen in the therapy of psoriasis. Experimental Dermatology, 1992, 1, 46-51.	1.4	27
45	How to improve the risk-benefit ratio of cyclosporin therapy for psoriasis. Clinical and Experimental Dermatology, 1992, 17, 16-19.	0.6	5
46	Bath-water compared with oral delivery of 8-methoxypsoralen PUVA therapy for chronic plaque psoriasis. British Journal of Dermatology, 1992, 127, 392-395.	1.4	101
47	Photoinduced cutaneous inflammatory response by psoralens. Journal of Photochemistry and Photobiology B: Biology, 1992, 14, 125-137.	1.7	3
48	A trial of accelerated PUVA in psoriasis. Clinical and Experimental Dermatology, 1993, 18, 297-299.	0.6	12
49	Prevalence of skin and other cancers in patients with psoriasis. Clinical and Experimental Dermatology, 1993, 18, 401-404.	0.6	27
50	Narrow-band (TL-01) UVB air-conditioned phototherapy for chronic severe adult atopic dermatitis. British Journal of Dermatology, 1993, 128, 49-56.	1.4	172
51	Oral psoralen photochemotherapy in severe childhood atopic eczema: an update. British Journal of Dermatology, 1993, 129, 431-436.	1.4	74
52	PUVA and cancer: a case-control study. British Journal of Dermatology, 1993, 129, 39-41.	1.4	34
53	DERMATOEPIDEMIOLOGY. PART I: EPIDEMIOLOGIC METHODS. International Journal of Dermatology, 1993, 32, 251-256.	0.5	11
54	p53 immunoreactivity in cutaneous PUVA tumors is similar to that in other non-melanoma skin neoplasms. Journal of Cutaneous Pathology, 1993, 20, 435-441.	0.7	12
55	THE EXCITATION OF 8-METHOXYPSORALEN WITH VISIBLE LIGHT: REVERSED PHASE HPLC QUANTITATION OF MONOADDUCTS and CROSS-LINKS. Photochemistry and Photobiology, 1993, 57, 1007-1009.	1.3	33
56	Minimising the Risks of PUVA Treatment. Drug Safety, 1993, 8, 340-349.	1.4	16
57	Factors Affecting the Development of Skin Cancer after Scalp Irradiation. Radiation Research, 1993, 135, 125.	0.7	19

#	ARTICLE	IF	Citations
58	PUVA, UVB, psoriasis, and nonmelanoma skin cancer. Journal of the American Academy of Dermatology, 1993, 29, 1013-1022.	0.6	128
59	An approach to the treatment of moderate to severe psoriasis with rotational therapy. Journal of the American Academy of Dermatology, 1993, 28, 454-459.	0.6	138
60	Would DNA Repair Assessment Benefit Patient Management?. Annals of Clinical Biochemistry, 1993, 30, 121-128.	0.8	1
61	Vitiligo: An Overview of Therapeutic Approaches. Dermatologic Clinics, 1993, 11, 325-338.	1.0	70
62	The specific effects of 8-methoxypsoralen photoadducts on cell growth: HPLC analysis of monoadduct and crosslink formation in cells exposed to split-dose treatment. Journal of Photochemistry and Photobiology B: Biology, 1994, 22, 17-21.	1.7	21
63	British Photodermatology Group guidelines for PUVA. British Journal of Dermatology, 1994, 130, 246-255.	1.4	214
64	Erythemal and therapeutic response of psoriasis to PUVA using high-dose UVA. British Journal of Dermatology, 1994, 131, 667-672.	1.4	28
65	Calcipotriol improves the response of psoriasis to PUVA. British Journal of Dermatology, 1994, 130, 79-82.	1.4	107
66	INACTIVATION OF VIRUSES IN HUMAN CELLULAR BLOOD COMPONENTS. Vox Sanguinis, 1994, 67, 211-216.	0.7	9
67	Methoxypsoralen phototherapy oftransitional cell carcinoma. Urology, 1994, 44, 842-846.	0.5	16
68	Metastatic squamous-cell carcinoma in patient receiving PUVA. Lancet, The, 1994, 344, 1157.	6.3	6
69	Photochemotherapy beyond psoriasis. Journal of the American Academy of Dermatology, 1994, 31, 775-790.	0.6	68
70	Risk of secondary cutaneous malignancies in patients with long-standing mycosis fungoides. Journal of the American Academy of Dermatology, 1994, 30, 201-204.	0.6	49
71	I. Sun exposure, UVA lamps and risk of skin cancer: Epidemiological studies. European Journal of Cancer, 1994, 30, 550-552.	1.3	7
72	Cutaneous carcinoma and PUVA lentigines in Thai patients treated with oral PUVA. Photodermatology Photoimmunology and Photomedicine, 1995, 11, 174-177.	0.7	11
73	UV-induced skin cancer in a hairless mouse model. BioEssays, 1995, 17, 651-660.	1.2	164
74	A comparison of twice-weekly MPD-PUVA and three times-weekly skin typing-PUVA regimens for the treatment of psoriasis. British Journal of Dermatology, 1995, 133, 417-422.	1.4	39
75	p53 immunoreactivity is uncommon in primary cutaneous lymphoma. British Journal of Dermatology, 1995, 132, 353-358.	1.4	29

#	Article	IF	CITATIONS
76	Nonmelanoma skin cancer. Postgraduate Medicine, 1995, 98, 39-58.	0.9	17
78	PUVA for Psoriasis. Dermatologic Clinics, 1995, 13, 851-866.	1.0	32
79	Cutaneous Malignancies in Patients Treated With Psoralen Photochemotherapy (PUVA) for Vitiligo. Archives of Dermatology, 1995, 131, 734.	1.7	22
80	Human Papillomavirus and Widespread Cutaneous Carcinoma After PUVA Photochemotherapy. Archives of Dermatology, 1995, 131, 701.	1.7	28
81	British Photodermatology Group guidelines for PUVA. Journal of the American Academy of Dermatology, 1995, 32, 120.	0.6	21
82	Etiology and pathogenesis of basal cell carcinoma. Clinics in Dermatology, 1995, 13, 527-536.	0.8	67
83	Etiology and pathogenesis of squamous cell carcinoma. Clinics in Dermatology, 1995, 13, 537-543.	0.8	30
84	Treatment of Psoriasis. New England Journal of Medicine, 1995, 332, 581-589.	13.9	352
85	Skin cancer in transplant recipients. Transplantation Reviews, 1995, 9, 1-16.	1.2	21
86	Phototherapy for Children. Pediatric Dermatology, 1996, 13, 415-418.	0.5	28
87	Dermatologic diagnosis and treatment of itchy redevelids. Survey of Ophthalmology, 1996, 40, 293-306.	1.7	59
89	Treatment of psoriasis with polyethylene sheet bath PUVA. Journal of the American Academy of Dermatology, 1996, 35, 208-210.	0.6	22
90	Response of PUVA-induced keratoses to etretinate. Journal of the American Academy of Dermatology, 1996, 35, 120-123.	0.6	7
91	Signature p53 mutation at DNA cross-linking sites in 8-methoxypsoralen and ultraviolet A (PUVA)-induced murine skin cancers Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 7961-7965.	3.3	67
92	Psoralen Photobiology: Recent Advances. Photochemistry and Photobiology, 1996, 63, 553-557.	1.3	34
93	Are stress Proteins induced during PUVA therapy?. British Journal of Dermatology, 1996, 134, 892-899.	1.4	1
94	8-MOP PUVA for psoriasis: a comparison of a minimal phototoxic dose-based regimen with a skin-type approach. British Journal of Dermatology, 1996, 135, 248-254.	1.4	39
95	Cutaneous neoplasia following PUVA therapy for psoriasis. British Journal of Dermatology, 1996, 134, 639-642.	1.4	73

#	Article	IF	CITATIONS
96	Nonâ€Melanoma Skin Tumors Occurring on a Japanese Psoriatic Patient Treated with Long Term Photochemotherapy. Journal of Dermatology, 1997, 24, 552-553.	0.6	2
97	Disease Management of Atopic Dermatitis: a Practice Parameter. Annals of Allergy, Asthma and Immunology, 1997, 79, 197-211.	0.5	101
98	Photochemotherapy. Clinics in Dermatology, 1997, 15, 769-780.	0.8	26
99	Psoralen photochemotherapy for vitiligo. Clinics in Dermatology, 1997, 15, 921-926.	0.8	51
100	Squamous Cell and Adnexal Carcinomas of the Skin. Clinics in Plastic Surgery, 1997, 24, 687-703.	0.7	14
101	p53 Mutation in Squamous Cell Carcinomas from Psoriasis Patients Treated with Psoralen + UVA (PUVA). Journal of Investigative Dermatology, 1997, 109, 238-243.	0.3	63
102	Detection of human papillomavirus DNA in squamous cell carcinomas of a patient with mycosis fungoides: report of a case. Journal of Cutaneous Pathology, 1997, 24, 47-50.	0.7	4
103	Guidelines for the use of phototherapy and photochemotherapy in Ireland. Irish Journal of Medical Science, 1997, 166, 92-97.	0.8	9
104	Dermatoepidemiology. II: Causal inference established by a rule called "ASSOCIATED". International Journal of Dermatology, 1997, 36, 412-415.	0.5	6
105	The variable response of plaque psoriasis after a single treatment with topical 5-aminolaevulinic acid photodynamic therapy. British Journal of Dermatology, 1997, 137, 743-749.	1.4	27
106	Multiple squamous cell carcinomas in a psoriatic patient following high-dose photochemotherapy and cyclosporin treatment: response to long-term acitretin maintenance. British Journal of Dermatology, 1997, 136, 275-278.	1.4	51
107	Synthesis of angelicin heteroanalogues: preliminary photobiological and pharmacological studies. Il Farmaco, 1998, 53, 602-610.	0.9	17
108	Cultivation of human keratinocyte stem cells: current and future clinical applications. Medical and Biological Engineering and Computing, 1998, 36, 778-790.	1.6	67
109	Detection of Human Papillomavirus DNA in PUVA-Associated Non-Melanoma Skin Cancers. Journal of Investigative Dermatology, 1998, 111, 123-127.	0.3	68
110	Multiple squamous cell carcinomas in situ in vitiligo lesions after long-term PUVA therapy. Journal of the American Academy of Dermatology, 1998, 38, 268-270.	0.6	76
111	Squamous cell cancer: A practical approach. Seminars in Cutaneous Medicine and Surgery, 1998, 17, 80-95.	1.6	92
112	Skin disorders that improve by exposure to sunlight. Clinics in Dermatology, 1998, 16, 59-65.	0.8	23
113	Recognition and Treatment of Psoriasis. Drugs and Aging, 1998, 12, 177-190.	1.3	23

#	Article	IF	CITATIONS
114	Nonsurgical Repigmentation Therapies in Vitiligo. Archives of Dermatology, 1998, 134, 1532-40.	1.7	226
115	Assays for Photocarcinogenesis: Relevance of Animal Models. International Journal of Toxicology, 1998, 17, 577-588.	0.6	12
116	Oral Psoralen and Ultraviolet-A Light (PUVA) Treatment of Psoriasis and Persistent Risk of Nonmelanoma Skin Cancer. Journal of the National Cancer Institute, 1998, 90, 1278-1284.	3.0	265
117	Consensus Workshop on the Toxic Effects of Long-term PUVA Therapy. Archives of Dermatology, 1998, 134, 595-8.	1.7	125
118	Risk of Squamous Cell Carcinoma and Methoxsalen (Psoralen) and UV-A Radiation (PUVA). Archives of Dermatology, 1998, 134, 1582-5.	1.7	197
119	Trimethylpsoralen Bath PUVA Is a Remittive Treatment for Psoriasis Vulgaris. Archives of Dermatology, 1998, 134, 1263-8.	1.7	27
120	Basal cell carcinoma. Journal of the Royal Society of Medicine, 1998, 91, 585-588.	1.1	26
121	Excess Mortality Related to Alcohol and Smoking Among Hospital-Treated Patients With Psoriasis. Archives of Dermatology, 1999, 135, 1490-3.	1.7	176
122	Combination low-dose cyclosporin (Neoral) and hydroxyurea for severe recalcitrant psoriasis. British Journal of Dermatology, 1999, 140, 186-187.	1.4	16
123	Malignant tumours and psoriasis: a follow-up study. British Journal of Dermatology, 1999, 140, 237-242.	1.4	122
124	Large increments in psoralen?ultraviolet A (PUVA) therapy are unsuitable for fair-skinned individuals with psoriasis. British Journal of Dermatology, 1999, 140, 661-666.	1.4	20
125	PUVA and cancer risk: the Swedish follow-up study. British Journal of Dermatology, 1999, 141, 108-112.	1.4	231
126	Multiple squamous cell carcinomas following photochemotherapy for atopic eczema. Clinical and Experimental Dermatology, 1999, 24, 337-337.	0.6	5
127	Green Tea Protects Against Psoralen Plus Ultraviolet A-Induced Photochemical Damage to Skin1. Journal of Investigative Dermatology, 1999, 113, 1070-1075.	0.3	71
128	Plasma antioxidant defense in actinic keratosis and basal cell carcinoma. Journal of the European Academy of Dermatology and Venereology, 1999, 13, 96-101.	1.3	35
129	PUVAâ€induced lymphocyte apoptosis: Mechanism of action in psoriasis. Photodermatology Photoimmunology and Photomedicine, 1999, 15, 22-27.	0.7	77
130	DNA–psoralens molecular recognition using molecular dynamics. Il Farmaco, 1999, 54, 202-212.	0.9	4
131	PUVA (8-methoxy-psoralen plus ultraviolet A) induces the formation of 8-hydroxy-2′-deoxyguanosine and DNA fragmentation in calf thymus DNA and human epidermoid carcinoma cells. Free Radical Biology and Medicine, 1999, 27, 127-133.	1.3	46

#	Article	IF	CITATIONS
132	Half-side comparison of erythemogenic versus suberythemogenic UVA doses in oral photochemotherapy of psoriasis. Journal of the American Academy of Dermatology, 1999, 41, 408-413.	0.6	16
133	Improving the safety profile of long-term PUVA therapy. Journal of the American Academy of Dermatology, 1999, 41, 496-497.	0.6	5
134	PUVA therapy: current concerns in Japan. Journal of Dermatological Science, 1999, 19, 89-105.	1.0	10
135	Basosquamous Carcinoma after Ultraviolet Therapy with Artificial Sunlight. Journal of Dermatology, 1999, 26, 527-531.	0.6	1
136	Secondary Malignant Neoplasms in 71 Patients With Sézary Syndrome. Archives of Dermatology, 1999, 135, 1381-5.	1.7	46
137	Comparison of calcipotriol-PUVA with conventional PUVA in the treatment of psoriasis. Journal of Dermatological Treatment, 2000, 11, 125-130.	1.1	8
138	Guidelines for topical PUVA: a report of a workshop of the British Photodermatology Group. British Journal of Dermatology, 2000, 142, 22-31.	1.4	111
139	Photobiological properties of 1-(3′-hydroxypropyl)-4,6,8-trimethylfuro[2,3-h]quinolin-2(1H)-one, a new furocoumarin analogue. Il Farmaco, 2000, 55, 650-658.	0.9	10
140	DNA Damage Induced by 4,6,8,9-Tetramethyl-2H-furo[2,3-h]quinolin-2-one, a New Furocoumarin Analog: Photochemical Mechanisms. Photochemistry and Photobiology, 2000, 71, 254-262.	1.3	17
141	Current Treatment Options in Psoriasis. Hospital Practice (1995), 2000, 35, 93-107.	0.5	9
142	p53 mutations experimentally induced by 8-methoxypsoralen plus UVA (PUVA) differ from those found in human skin cancers in PUVA-treated patients. Mutagenesis, 2000, 15, 127-132.	1.0	13
143	Treatment of generalized vitiligo in children with narrow-band (TL-01) UVB radiation therapyâ [*] †, â [*] †â [*] †. Journal of the American Academy of Dermatology, 2000, 42, 245-253.	0.6	332
144	PUVA-related punctate keratoses of the hands and feet. Journal of the American Academy of Dermatology, 2000, 42, 476-479.	0.6	7
145	Treatment of psoriasis. Part 1. Topical therapy and phototherapy. Journal of the American Academy of Dermatology, 2001, 45, 487-502.	0.6	207
146	Vitiligo. American Journal of Clinical Dermatology, 2001, 2, 167-181.	3.3	173
147	Skin pigmentation enhancers. Comprehensive Series in Photosciences, 2001, 3, 637-675.	0.3	6
148	Laser Resurfacing-Induced Hypopigmentation. Dermatologic Surgery, 2001, 27, 515-520.	0.4	0
149	Clinicopathologic Variants of Cutaneous Squamous Cell Carcinoma. Advances in Anatomic Pathology, 2001, 8, 27-36.	2.4	73

#	Article	IF	CITATIONS
150	Induction of unscheduled DNA synthesis in hairless mouse epidermis by 8-methoxypsoralen plus ultraviolet A(PUVA) Journal of Toxicological Sciences, 2001, 26, 1-8.	0.7	11
151	Induction and Excretion of Ultraviolet-Induced 8-Oxo-2′-deoxyguanosine and Thymine Dimers In Vivo: Implications for PUVA. Journal of Investigative Dermatology, 2001, 116, 281-285.	0.3	54
152	Laser Resurfacing-Induced Hypopigmentation: Histologic Alterations and Repigmentation with Topical Photochemotherapy. Dermatologic Surgery, 2001, 27, 515-520.	0.4	53
153	Evidence-Based Medicine for Dermatologic Surgeons: Concepts in Critical Appraisal of Information. Dermatologic Surgery, 2001, 27, 511-514.	0.4	7
154	Skin pigmentation enhancers. Journal of Photochemistry and Photobiology B: Biology, 2001, 63, 148-161.	1.7	53
155	Difurocoumarins: Psoralen analogs as photochemotherapeutic agents. Journal of Heterocyclic Chemistry, 2001, 38, 431-434.	1.4	8
157	Adverse effects with PUVA and UVB phototherapy. Journal of Dermatological Treatment, 2001, 12, 101-105.	1.1	36
158	Comparative Tolerability of Systemic Treatments for Plaque-Type Psoriasis. Drug Safety, 2002, 25, 913-927.	1.4	64
159	Treatment of vitiligo with the 308-nm excimer laser: A pilot study. Journal of the American Academy of Dermatology, 2002, 46, 727-731.	0.6	165
160	The persistent risk of genital tumors among men treated with psoralen plus ultraviolet A (PUVA) for psoriasis. Journal of the American Academy of Dermatology, 2002, 47, 33-39.	0.6	97
161	Novel angular furo and thieno-quinolinones: synthesis and preliminary photobiological studies. Bioorganic and Medicinal Chemistry, 2002, 10, 743-751.	1.4	56
162	DNA damage and biological effects induced by photosensitization with new N1-unsubstituted furo [2,3-h]quinolin-2(1H)-ones. Bioorganic and Medicinal Chemistry, 2002, 10, 2835-2844.	1.4	24
163	Incidence and Risk Factors Associated with a Second Squamous Cell Carcinoma or Basal Cell Carcinoma in Psoralen + Ultraviolet A Light-treated Psoriasis Patients. Journal of Investigative Dermatology, 2002, 118, 1038-1043.	0.3	43
164	Synthesis of thio- and oxo-analogues of isopsoralen. Tetrahedron, 2002, 58, 2831-2837.	1.0	20
165	In silico rationalization of the structural and physicochemical requirements for photobiological activity in angelicine derivatives and their heteroanalogues. Journal of Computer-Aided Molecular Design, 2003, 17, 53-64.	1.3	5
166	Treatment of polymorphic light eruption. Photodermatology Photoimmunology and Photomedicine, 2003, 19, 217-227.	0.7	42
167	The Increased Risk of Skin Cancer Is Persistent After Discontinuation of Psoralen+Ultraviolet A: A Cohort Study. Journal of Investigative Dermatology, 2003, 121, 252-258.	0.3	201
168	Electrospray mass spectrometry in the differentiation of some isomeric trimethylfurocoumarins. Rapid Communications in Mass Spectrometry, 2003, 17, 2781-2787.	0.7	7

#	ARTICLE	IF	CITATIONS
169	Verrucous scrotal carcinoma in a patient with hypospadias: is there a possible association?. Urology, 2003, 61, 224.	0.5	6
170	Basal cell carcinoma. BMJ: British Medical Journal, 2003, 327, 794-798.	2.4	343
171	Longâ€Term Continuous <i>versus</i> Intermittent Cyclosporin: Therapy for Psoriasis. Journal of Dermatology, 2003, 30, 290-298.	0.6	29
173	Pediatric psoriasis and psoriatic arthritis. Dermatologic Therapy, 2004, 17, 364-375.	0.8	59
174	A randomized cross-over study to compare PUVA and extracorporeal photopheresis in the treatment of plaque stage (T2) mycosis fungoides. Clinical and Experimental Dermatology, 2004, 29, 231-236.	0.6	41
175	Phototherapy and PUVA photochemotherapy in children. Photodermatology Photoimmunology and Photomedicine, 2004, 20, 69-75.	0.7	33
176	latrogenic skin cancer: induction by psoralen/ultraviolet A and immunosuppression of organ transplant recipients. Photodermatology Photoimmunology and Photomedicine, 2004, 20, 289-296.	0.7	6
177	Disposition of 4,6,4′-trimethylangelicin in mice maintained in the dark and after UVA irradiation. Il Farmaco, 2004, 59, 793-801.	0.9	1
178	Parallel solid-phase synthesis of 2-arylamino-6H-pyrano[2,3-f]benzimidazole-6-ones. Tetrahedron, 2004, 60, 8605-8612.	1.0	9
182	Review of therapy of psoriasis: the prebiologic armamentarium. Dermatologic Clinics, 2004, 22, 379-388.	1.0	5
183	Uncommon causes of leg ulceration and lesions not to be missed. British Journal of Community Nursing, 2004, 9, S23-S28.	0.2	1
185	Effect of ethnicity on the risk of developing nonmelanoma skin cancer following long-term PUVA therapy. International Journal of Dermatology, 2005, 44, 1016-1021.	0.5	55
186	Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks. British Journal of Dermatology, 2005, 152, 597-615.	1.4	165
188	Nonâ€melanoma skin cancer in patients with atopic dermatitis treated with topical tacrolimus. Journal of Dermatological Treatment, 2005, 16, 149-153.	1.1	46
190	Basal Cell Carcinomas of the Eyelids. Ophthalmologica, 2005, 219, 57-71.	1.0	96
191	A clinician's paradigm in the treatment of atopic dermatitis. Journal of the American Academy of Dermatology, 2005, 53, S70-S77.	0.6	34
193	Treatment of Psoriasis. Taehan Uihak Hyophoe Chi the Journal of the Korean Medical Association, 2006, 49, 150.	0.1	0
194	Going beyond Skin Typing: Predicting Skin Cancer Risk and Implications for Phototherapy Risk-Benefit Calculation. Psoriasis Forum, 2006, 12a, 6-9.	0.1	0

#	Article	IF	CITATIONS
195	Skin cancers or premalignant lesions occur in half of high-dose PUVA patients. British Journal of Dermatology, 2006, 131, 215-219.	1.4	80
196	Basal cell carcinoma following amiodarone therapy. British Journal of Dermatology, 1995, 133, 148-149.	1.4	28
197	Predictive value of phenotypic variables for skin cancer: Risk assessment beyond skin typing. International Journal of Dermatology, 2006, 45, 1275-1283.	0.5	12
198	PUVA treatment of the nasal cavity improves the clinical symptoms of allergic rhinitis and inhibits the immediate-type hypersensitivity reaction in the skin. Journal of Photochemistry and Photobiology B: Biology, 2006, 83, 21-26.	1.7	23
199	Treatment of Vitiligo Using the 308-nm Excimer Laser. Photomedicine and Laser Surgery, 2006, 24, 354-357.	2.1	45
200	In vivo photochemical skin micronucleus test using a sunlight simulator: Detection of 8-methoxypsoralen and benzo[a]pyrene in hairless mice. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2007, 631, 1-8.	0.9	15
201	Current and future management of psoriasis. Lancet, The, 2007, 370, 272-284.	6.3	268
202	Overview of Dermatological Diseases. , 2007, , 935-955.		0
203	Fototerapia: aplicaçÃμes clÃnicas. Anais Brasileiros De Dermatologia, 2007, 82, 7-21.	0.5	13
204	Ultraviolet light phototherapy for allergic rhinitis. Journal of Photochemistry and Photobiology B: Biology, 2007, 87, 58-65.	1.7	45
205	A Randomized Comparison of Selective Broadband UVB and Narrowband UVB in the Treatment of Psoriasis. Journal of Investigative Dermatology, 2007, 127, 1641-1646.	0.3	56
206	The challenge of follow-up in narrowband ultraviolet B phototherapy. British Journal of Dermatology, 2007, 157, 344-349.	1.4	34
208	Phototherapy in Childhood. Pediatric Dermatology, 2008, 25, 599-605.	0.5	59
209	Guideline for the diagnosis and management of vitiligo. British Journal of Dermatology, 2008, 159, 1051-1076.	1.4	278
210	The increase in melanoma: Are dietary furocoumarins responsible?. Medical Hypotheses, 2008, 70, 855-859.	0.8	39
211	latrogenic agents causing cancer. Biomedicine and Pharmacotherapy, 2008, 62, 197.	2.5	0
212	Detection of high-risk human papillomaviruses in verrucae of patients with mycosis fungoides and Sézary syndrome: a case series. International Journal of Dermatology, 2009, 48, 598-602.	0.5	7
213	Relative Photomutagenicity of Furocoumarins and Limettin in the Hypoxanthine Phosphoribosyl Transferase Assay in V79 Cells. Chemical Research in Toxicology, 2009, 22, 1639-1647.	1.7	13

#	ARTICLE	IF	CITATIONS
214	Randomized, double-blind, placebo-controlled evaluation of the efficacy of oral psoralen plus ultraviolet A for the treatment of plaque-type psoriasis using the Psoriasis Area Severity Index score (improvement of 75% or greater) at 12 weeks. Journal of the American Academy of Dermatology, 2009, 61, 793-798.	0.6	33
215	Phototherapy for Vitiligo. , 2009, , 171-187.		O
216	Basal Cell and Squamous Cell Skin Cancers. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, 836-864.	2.3	98
217	Design, synthesis and docking studies of new furobenzopyranones and pyranobenzopyranones as photoreagent towards DNA and as antimicrobial agents. European Journal of Medicinal Chemistry, 2010, 45, 317-325.	2.6	18
219	Inhibition of Histidine Ammonia Lyase by 8â€Methoxypsoralen and Psoralenâ€oxidized Photoproducts. Photochemistry and Photobiology, 2010, 86, 1272-1277.	1.3	3
220	A Review of the Efficacy and Safety of Combined Methotrexate and Ultraviolet B Phototherapy versus Ultraviolet B Phototherapy Alone in the Treatment of Psoriasis. Psoriasis Forum, 2010, 16a, 26-32.	0.1	0
221	Malignancy concerns with psoriasis treatments using phototherapy, methotrexate, cyclosporin, and biologics: facts and controversies. Clinics in Dermatology, 2010, 28, 88-92.	0.8	71
222	Application of the concept of relative photomutagenic potencies to selected furocoumarins in V79 cells. Toxicology in Vitro, 2010, 24, 558-566.	1.1	24
223	HIV-associated psoriasis: pathogenesis, clinical features, and management. Lancet Infectious Diseases, The, 2010, 10, 470-478.	4.6	144
224	Penile cancer: an update. International Journal of Urological Nursing, 2011, 5, 97-106.	0.1	3
227	No Evidence for Increased Skin Cancer Risk in Koreans with Skin Phototypes III-V Treated with Narrowband UVB Phototherapy Acta Dermato-Venereologica, 2011, 91, 40-43.	0.6	27
228	A Review of the Journal of Investigative Dermatology's Most Cited Publications over the Past 25 Years and the Use of Developing Bibliometric Methodologies to Assess Journal Quality. Journal of Investigative Dermatology, 2012, 132, 1050-1060.	0.3	9
229	Facial skin cancers: general information and an overview of treatment methods. Advances in Dermatology and Allergology, 2012, 4, 240-255.	1.0	2
231	Major furocoumarins in grapefruit juice II: Phototoxicity, photogenotoxicity, and inhibitory potency vs. cytochrome P450 3A4 activity. Food and Chemical Toxicology, 2012, 50, 756-760.	1.8	40
232	The risk of developing nonâ€melanoma skin cancer, lymphoma and melanoma in patients with psoriasis in Taiwan: a 10â€year, populationâ€based cohort study. International Journal of Dermatology, 2012, 51, 1454-1460.	0.5	34
233	Integrated Approach to Comorbidity in Patients With Psoriasis. Actas Dermo-sifiliogr $ ilde{A}_i$ ficas, 2012, 103, 1-64.	0.2	8
234	Carcinogenic risks of Psoralen UVâ€A therapy and Narrowband UVâ€B therapy in chronic plaque psoriasis: a systematic literature review. Journal of the European Academy of Dermatology and Venereology, 2012, 26, 22-31.	1.3	246
235	Narrow-band ultraviolet B phototherapy versus broad-band ultraviolet B or psoralen-ultraviolet A photochemotherapy for psoriasis. The Cochrane Library, 2016, 2016, CD009481.	1.5	41

#	ARTICLE	IF	CITATIONS
236	Phototoxicity of Herbal Plants and Herbal Products. Journal of Environmental Science and Health, Part C: Environmental Carcinogenesis and Ecotoxicology Reviews, 2013, 31, 213-255.	2.9	26
237	Severe Burn Injuries Induced by PUVA Chemotherapy. Journal of Burn Care and Research, 2013, 34, e195-e200.	0.2	4
238	Squamous Cell Carcinoma. JAMA Dermatology, 2013, 149, 1448.	2.0	6
240	Squamous cell carcinoma of the scrotum - still an occupational hazard. Indian Journal of Industrial Medicine, 2014, 18, 150.	0.4	2
241	Psoriasis and comorbidities: links and risks. Clinical, Cosmetic and Investigational Dermatology, 2014, 7, 119.	0.8	105
242	Ultraviolet radiation (UVR) dosimetry system and the use of Ge-doped silica optical fibres. Radiation Physics and Chemistry, 2014, 104, 129-133.	1.4	6
244	Photosensitizing medications and photocarcinogenesis. Photodermatology Photoimmunology and Photomedicine, 2014, 30, 8-14.	0.7	43
245	UV-Based Therapy. Dermatologic Clinics, 2014, 32, 399-413.	1.0	32
246	Cutaneous Carcinogenic Risk of Phototherapy: An Updated Comprehensive Review. Journal of Psoriasis and Psoriatic Arthritis, 2015, 1, 44-51.	0.3	15
247	"Mata de tristeza!― representações sociais de pessoas com vitiligo atendidas na Farmácia Universitária da Universidade Federal do Rio de Janeiro, Brasil. Interface: Communication, Health, Education, 2016, 20, 953-965.	0.4	3
248	Phototherapy for Pityriasis Lichenoides in the Pediatric Population: A Review of the Published Literature. American Journal of Clinical Dermatology, 2016, 17, 583-591.	3.3	17
249	The dark side of the light: Phototherapy adverse effects. Clinics in Dermatology, 2016, 34, 556-562.	0.8	32
250	Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same?. Seminars in Arthritis and Rheumatism, 2016, 46, 291-304.	1.6	119
251	British Association of Dermatologists and British Photodermatology Group guidelines for the safe and effective use of psoralen–ultraviolet A therapy 2015. British Journal of Dermatology, 2016, 174, 24-55.	1.4	79
252	Melanoma and non-melanoma skin cancer in psoriatic patients treated with high-dose phototherapy. Journal of Dermatological Treatment, 2016, 27, 443-447.	1.1	36
253	Diagnosis, Staging, and Treatment of Chronic Graft-Versus-Host Disease. , 2017, , 125-138.		0
254	Addressing the Question: Phototherapy and the Risk of Skin Cancer. , 2017, , 167-170.		0
255	Periocular basal cell carcinoma: a comprehensive review. Expert Review of Ophthalmology, 2017, 12, 221-232.	0.3	1

#	Article	IF	CITATIONS
256	The risk of malignancy among biologic-na \tilde{A} -ve pediatric psoriasis patients: A retrospective cohort study in a US claims database. Journal of the American Academy of Dermatology, 2017, 77, 293-301.e1.	0.6	11
257	Interventions for polymorphic light eruption. The Cochrane Library, 0, , .	1.5	0
258	HIV-associated psoriasis. Actas Dermo-sifiliográficas, 2018, 109, 303-311.	0.2	7
259	Psoriasis asociada al VIH. Actas Dermo-sifiliográficas, 2018, 109, 303-311.	0.2	14
260	Comparison between 8â€methoxypsoralen and 5â€aminolevulinic acid in killing T cells of photopheresis patients <i>ex vivo</i> . Lasers in Surgery and Medicine, 2018, 50, 469-475.	1.1	14
261	A Perspective on the Use of NB-UVB Phototherapy vs. PUVA Photochemotherapy. Frontiers in Medicine, 2018, 5, 184.	1.2	49
263	The Science and (Lost) Art of Psoralen Plus UVA Phototherapy. Dermatologic Clinics, 2020, 38, 11-23.	1.0	22
264	Selective Killing of Activated T Cells by 5-Aminolevulinic Acid Mediated Photodynamic Effect: Potential Improvement of Extracorporeal Photopheresis. Cancers, 2020, 12, 377.	1.7	9
266	Drugâ€induced photosensitivity: culprit drugs, potential mechanisms and clinical consequences. JDDG - Journal of the German Society of Dermatology, 2021, 19, 19-29.	0.4	31
267	The Appropriateness of Curettage and Electrodesiccation for the Treatment of Basal Cell Carcinomas. Archives of Dermatology, 2000, 136, 800-800.	1.7	12
268	Photosensitizing Compounds in the Treatment of Psoriasis. Novartis Foundation Symposium, 1989, 146, 159-170.	1.2	6
269	Nonmelanoma Cutaneous Malignancies. , 2006, , 1102-1118.		3
270	Mutagenic Effects of Psoralen-Induced Photoadducts and their Repair in Eukaryotic Cells. , 1991, , 933-950.		3
271	Mutagenesis Photoinduced by Psoralens in Yeast. , 1991, , 235-251.		1
272	Ultraviolet Radiation and Skin Cancer: Epidemiological Data from the United States and Canada. , 1993, , 295-344.		20
274	PUVA, Psoralens and Skin Cancer. , 1997, , 416-424.		1
275	Erythematöse, erythematosquamöse und papulöse Hauterkrankungen. , 1996, , 523-611.		1
276	Erythemato-Papulo-Squamous Diseases. , 2000, , 571-647.		9

#	Article	IF	Citations
277	Erythematous and Erythematosquamous Skin Diseases., 1991,, 403-466.		4
278	Risk of malignancies in patients treated with Sandimmun $\hat{A}^{\text{@}}$ for autoimmune diseases. , 1996, , 141-148.		3
279	Spongiotic, psoriasiform and pustular dermatoses. , 2012, , 180-218.		20
280	Tumors of the surface epithelium. , 2012, , 1076-1149.		18
281	SQUAMOUS-CELL CARCINOMA OF THE SCROTUM. Urologic Clinics of North America, 1992, 19, 397-405.	0.8	51
282	Carcinogenesis: A Fifty-Year Historical Perspective Journal of Investigative Dermatology, 1989, 92, 121S-131S.	0.3	5
283	The State of Research in Cutaneous Biology: A Perspective in the 50th Anniversary Year of the Society for Investigative Dermatology and The Journal of Investigative Dermatology Journal of Investigative Dermatology, 1989, 92, 179S-197S.	0.3	2
284	Are stress Proteins induced during PUVA therapy?. British Journal of Dermatology, 1996, 134, 892-899.	1.4	1
285	The variable response of plaque psoriasis after a single treatment with topical 5-aminolaevulinic acid photodynamic therapy. British Journal of Dermatology, 1997, 137, 743-749.	1.4	56
286	Multiple squamous cell carcinomas in a psoriatic patient following high–dose photochemotherapy and cyclosporin treatment: response to long–term acitretin maintenance. British Journal of Dermatology, 1997, 136, 275-278.	1.4	16
287	Comparison of Urinary 8-Hydroxy-2'-deoxyguanosine in Patients Treated With Topical Corticosteroids, UV-B, and Psoralen UV-A Therapies. Archives of Dermatology, 2000, 136, 808-810.	1.7	0
288	Dermatology and Nutrition. , 2005, , .		O
289	Bade-PUVA-Therapie: Wo bist du geblieben?. Fortschritte Der Praktischen Dermatologie Und Venerologie, 2007, , 205-209.	0.0	0
290	A Case Of Scrotal Cancer With Inguinal Lymph Node Metastasis Treated By Multidisciplinary Modalities: A Case Report. The Internet Journal of Urology, 2007, 4, .	0.5	2
291	Carcinomes basocellulaires. , 2009, , 123-136.		0
292	Phototherapy. , 2012, , 1017-1022.		0
293	Carcinogenic Risk of UV Treatment. Nishinihon Journal of Dermatology, 2013, 75, 197-199.	0.0	0
294	History of Psoriasis. , 2014, , 1-7.		2

#	Article	IF	CITATIONS
295	Photochemotherapy. Handbook of Experimental Pharmacology, 1989, , 509-541.	0.9	1
296	Oral PUVA therapy for psoriasis vulgaris with M-DMR-TS type UVA irradiator Nishinihon Journal of Dermatology, 1989, 51, 325-328.	0.0	O
297	Ultraviolet Radiation Therapy of Atopic Eczema. , 1991, , 452-458.		0
298	Differentiation Of Basal Cell Carcinoma. Otolaryngologic Clinics of North America, 1993, 26, 37-56.	0.5	8
299	Ist UV-Therapie karzinogen?. Fortschritte Der Praktischen Dermatologie Und Venerologie, 1997, , 284-289.	0.0	0
300	Influences of UV Radiation in the Therapy of Psoriasis Vulgaris. , 1997, , 462-468.		O
301	Overall study on molecular pathways of skin cancer derived from Ultra- violet radiation as an environmental threat. Environment Conservation Journal, 2021, 16, 547-555.	0.1	3
302	Phototherapy., 2019, , 1-10.		O
303	Phototherapy., 2020, , 1279-1288.		0
305	Risk of cutaneous carcinogenesis with phototherapy in Indian subpopulation: A 10â€year analysis and a review of literature. Dermatologic Therapy, 2022, 35, e15536.	0.8	1
306	PUVA photochemotherapy and other phototherapy modalities. , 2013, , 279-290.e4.		1
307	Revisited the potential risks of carcinogenicity of phototherapy in patients with psoriasis. Vestnik Dermatologii I Venerologii, 2014, 90, 60-67.	0.2	1
308	Squamous cell carcinoma in a psoriasis patient after multiple courses of phototherapy. Vestnik Dermatologii I Venerologii, 2015, 91, 92-98.	0.2	1
309	Incidence of skin malignancies in patients with vitiligo or psoriasis who received narrowband ultraviolet B phototherapy (308 nm/311 nm): A retrospective review of 3730 patients. Photodermatology Photoimmunology and Photomedicine, 2023, 39, 343-350.	yO.7	3
310	<scp>Bathâ€PUVA</scp> still represents a valuable treatment option for the subsets of psoriatic patients who are not eligible to or rejecting systemic treatments and are not responsive to <scp>NBâ€UVB</scp> phototherapy . . Photodermatology Photoimmunology and Photomedicine, 0, , .	0.7	0